congresses-banner

The content contained is subject

PublicationView

Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
Hematology
A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
Harry P. Erba
Poster
Quizartinib
SOHO 2024 Annual Meeting | September 4-7, 2024
Hematology
QuANTUM-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction and consolidation is associated with improved overall survival in newly diagnosed FLT3-ITD+ AML patients
Alexander E. Perl
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
Hematology
QuANTUM-First: Efficacy by age in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia
Pau Montesinos
Poster
Quizartinib
SOHO 2024 Annual Meeting | September 4-7, 2024
Hematology
QuANTUM-First: Efficacy by age in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia
Harry P. Erba
Oral
Quizartinib
EHA 2024 | June 13-16, 2024
Hematology
QuANTUM-First: Efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia who received continuation therapy
Mikkael A. Sekeres
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
Hematology
QuANTUM-First: Patient-reported outcomes in newly diagnosed Italicize FLT3-ITD+ acute myeloid leukemia patients receiving standard chemotherapy plus quizartinib or placebo
Esther Natalie Oliva
Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
Hematology
Valemetostat for patients with relapsed/refractory peripheral T-cell lymphomas: The phase 2 VALENTINE-PTCL01 trial
Steven M. Horwitz
Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
Hematology
Valemetostat monotherapy in patients with relapsed/refractory non-hodgkin lymphomas: Primary results from a phase 1 trial
Dai Maruyama

footer